While the virus hasn’t made a sustained leap into humans, vaccines and treatments are being developed ahead of an outbreak.

The doctor recommended getting updated flu vaccines annually to lower the risk of contracting the virus and be protected from ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for an IPO to fund development of vaccines that could compete with companies ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.

GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...

The new agreement comes at a time when GSK and CureVac have been at risk of falling behind in mRNA vaccines for respiratory diseases, with combined flu/COVID-19 candidates from Moderna and Pfizer ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

GSK said at an R&D update in the summer that it expects to have two mRNA candidates in clinical trials within 12 months and six within the next four years, including seasonal flu shots.